Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced Cancers with DDR2 or B-RAF Mutations
NCT01514864Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2012
- Primary completion
- Jul 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of dasatinib in non-small cell lung cancer (NSCLC), advanced cancer, sponsored by Bristol Myers Squibb. Started May 2012; status: terminated.
02
Drugs
dasatinib
03
Conditions
non-small cell lung cancer (NSCLC)advanced cancer
Beyond the preview
Go deeper on NCT01514864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514864.